Gartland A, Hipskind RA, Gallagher JA, Bowler WB. Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res 2001; 16: 846–56.
Solini A, Chiozzi P, Morelli A et al. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci 1999; 112: 297–305.
Solini A, Chiozzi P, Falzoni S et al. High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts. Diabetologia 2000; 43: 1248–56.
O’Reilly BA, Kosaka AH, Chang TK et al. A quantitative analysis of purinoceptor expression in human fetal and adult bladders. J Urol 2001; 165: 1730–4.
O’Reilly BA, Kosaka AH, Chang TK et al. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int 2001; 87: 617–22.
Slater NM, Barden JA, Murphy CR. Distributional changes of purinergic receptor subtypes P2X1–7 in uterine epithelial cells during early pregnancy. Histochem J 2000; 32: 365–72.
Tassell W, Slater M, Barden JA, Murphy CR. Endometrial cell death during early pregnancy in the rat. Histochem J 2000; 32: 373–9.
Lee HY, Bardini M, Burnstock G. P2X receptor immunoreactivity in the male genital organs of the rat. Cell Tissue Res 2000; 300: 321–30.
Greig AV, Linge C, Cambrey A, Burnstock G. Purinergic receptors are part of a signaling system for keratinocyte proliferation, differentiation and apoptosis in human fetal epidermis. J Invest Dermatol 2003; 121: 1145–9.
Li Q, Luo X, Zeng W, Muallem S. Cell-specific behaviour of P2X7 receptors in mouse parotid acinar and duct cells. J Biol Chem 2003; 278: 47554–61.
Cockcroft S, Gomperts BD. ATP induces nucleotide permeability in rat mast cells. Nature 1979; 279: 541–2.
Cockcroft S, Gomperts BD. The ATP4‒ receptor of rat mast cells. Biochem J 1980; 188: 789–98.
Gordon JL. Extracellular ATP: Effects, sources and fate. Biochem J 1986; 233: 309–19.
Steinberg TH, Silverstein SC. Extracellular ATP4‒ promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem 1987; 262: 3118–22.
Greenberg S, Di Virgilio F, Steinberg TH, Silverstein SC. Extracellular nucleotides mediate Ca2+ fluxes in J774 macrophages by two distinct mechanisms. J Biol Chem 1988; 263: 10337–43.
Surprenant A, Rassendren F, Kawashima E et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996; 272: 735–8.
Freist W, Verhey JF, Stuhmer W, Gauss DH. ATP binding site of P2X channel proteins: Structural similarities with class II aminoacyl–tRNA synthetases. FEBS Lett 1998; 434: 61–5.
Worthington RA, Smart ML, Gu BJ et al. Point mutations confer loss of ATP-induced human P2X7 receptor function. FEBS Lett 2002; 512: 43–6.
North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 2000; 40: 563–80.
North RA. The molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013–67.
Steinberg TH, Newman AS, Swanson JA, Silverstein SC. ATP4‒ permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J Biol Chem 1987; 262: 8884–8.
Di Virgilio F, Bronte V, Collavo D, Zanovello P. Responses of mouse lymphocytes to extracellular adenosine 5’-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 1989; 143: 1955–60.
Di Virgilio F. The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death. Immunol Today 1995; 16: 524–8.
Virginio C, MacKenzie A, North RA, Surprenant A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol 1999; 519: 335–46.
Ferrari D, Munerati M, Melchiorri L et al. Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am J Physiol 1994; 267: C886–92.
Chused TM, Apasov S, Sitkovsky M. Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. J Immunol 1996; 157: 1371–80.
Markwardt F, Lohn M, Bohm T, Klapperstuck M. Purinoceptor-operated cationic channels in human B lymphocytes. J Physiol 1997; 498: 143–51.
Pizzo P, Zanovello P, Bronte V, Di Virgilio F. Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. Biochem J 1991; 274: 139–44.
Rassendren F, Buell GN, Virginio C et al. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482–6.
Virginio C, Church D, North RA, Surprenant A. Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacology 1997; 36: 1285–94.
Watano T, Matsuoka I, Kimura J. Inhibitory effects of metals on ATP-induced current through P2X7 receptor in NG108-15 cells. Jpn J Pharmacol 2002; 89: 296–301.
Hu Y, Fisette PL, Denlinger LC et al. Purinergic receptor modulation of lipopolysaccharide signaling and inducible nitric-oxide synthase expression in RAW 264.7 macrophages. J Biol Chem 1998; 273: 27170–5.
Adriouch S, Dox C, Welge V et al. Cutting edge: A natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. J Immunol 2002; 169: 4108–12.
Le Stunff H, Auger R, Kanellopoulos J, Raymond MN. The Pro-451 to Leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. J Biol Chem 2004; 279: 16918–26.
Smart ML, Gu B, Panchal RG et al. P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem 2003; 278: 8853–60.
Gu BJ, Zhang W, Worthington RA et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135–42.
Sluyter R, Shemon AN, Barden JA, Wiley JS. Extracellular ATP increases cation fluxes in human erythrocytes by activation of the P2X7 receptor. J Biol Chem 2004; 279: 44749–55.
Gu BJ, Sluyter R, Skarratt KK et al. An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 2004; 279: 31287–95.
Wiley JS, Dao-Ung LP, Li C et al. An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 2003; 278: 17108–13.
Klapperstuck M, Buttner C, Schmalzing G, Markwardt F. Functional evidence of distinct ATP activation sites at the human P2X7 receptor. J Physiol 2001; 534: 25–35.
Smart ML, Panchal RG, Bowser DN et al. Pore formation is not associated with macroscopic redistribution of P2X7 receptors. Am J Physiol, Cell Physiol 2002; 283: C77–84.
Tatham PE, Lindau M. ATP-induced pore formation in the plasma membrane of rat peritoneal mast cells. J Gen Physiol 1990; 95: 459–76.
Coutinho-Silva R, Alves LA, de Carvalho AC et al. Characterization of P2Z purinergic receptors on phagocytic cells of the thymic reticulum in culture. Biochim Biophys Acta 1996; 1280:217–22.
Kochukov MY, Ritchie AK. A P2X7 receptor stimulates plasma membrane trafficking in the FRTL rat thyrocyte cell line. Am J Physiol Cell Physiol 2004; 287: C992–1002.
MacKenzie A, Wilson HL, Kiss-Toth E et al. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001; 15: 825–35.
Morelli A, Chiozzi P, Chiesa A et al. Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol Biol Cell 2003; 14: 2655–64.
Verhoef PA, Estacion M, Schilling W, Dubyak GR. P2X7 receptor-dependent blebbing and the activation of rho-effector kinases, caspases, and IL-1 beta release. J Immunol 2003; 170: 5728–38.
Kim M, Spelta V, Sim J et al. Differential assembly of rat purinergic P2X7 receptor in immune cells of the brain and periphery. J Biol Chem 2001; 276: 23262–7.
Kim M, Jiang LH, Wilson HL et al. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 2001; 20: 6347–58.
Adinolfi E, Kim M, Young MT et al. Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex negatively regulates P2X7 receptors. J Biol Chem 2003; 278: 37344–51.
Wilson HL, Wilson SA, Surprenant A, North RA. Epithelial Membrane Proteins Induce Membrane Blebbing and Interact with the P2X7 receptor C Terminus. J Biol Chem 2002; 277: 34017–23.
Denlinger LC, Fisette PL, Sommer JA et al. Cutting edge: The nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol 2001; 167: 1871–6.
Gargett CE, Cornish EJ, Wiley JS. Phospholipase D activation by P2Z-purinoceptor agonists in human lymphocytes is dependent on bivalent cation influx. Biochem J 1996; 313: 529–35.
Per Larsson K, Jon Hansen, Dissing S. The human SH-SY5Y neuroblastoma cell-line expresses a functional P2X7 purinoceptor that modulates voltage-dependent Ca2+ channel function. J Neurochem 2002; 83: 285–98.
Pannicke T, Fischer W, Biedermann B et al. P2X7 receptors in Müller glial cells from the human retina. J Neurosci 2000; 20: 5965–72.
Colomar A, Amedee T. ATP stimulation of P2X7 receptors activates three different ionic conductances on cultured mouse Schwann cells. Eur J Neurosci 2001; 14: 927–36.
Kimm-Brinson KL, Moeller PD, Barbier M et al. Identification of a P2X7 receptor in GH(4)C(1) rat pituitary cells: A potential target for a bioactive substance produced by Pfiesteria piscicida. Environ Health Perspect 2001; 109: 457–62.
Deuchars SA, Atkinson L, Brooke RE et al. Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci 2001; 21: 7143–52.
Sperlagh B, Kofalvi A, Deuchars J et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 2002; 81: 1196–211.
Armstrong JN, Brust TB, Lewis RG, MacVicar BA. Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci 2002; 22: 5938–45.
Kukley M, Stausberg P, Adelmann G et al. Ecto-nucleotidases and nucleoside transporters mediate activation of adenosine receptors on hippocampal mossy fibers by P2X7 receptor agonist 2’3’-O-(4-benzoylbenzoyl)-ATP. J Neurosci 2004; 24: 7128–39.
Sim JA, Young MT, Sung HY et al. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 2004; 24: 6307–14.
Duan S, Anderson CM, Keung EC et al. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 2003; 23: 1308–20.
Jacques-Silva MC, Rodnight R, Lenz G et al. P2X7 receptors stimulate AKT phosphorylation in astrocytes. Br J Pharmacol 2004; 141: 1106–17.
Murgia M, Hanau S, Pizzo P et al. Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 1993; 268: 8199–203.
Humphreys BD, Virginio C, Surprenant A et al. Isoquinolines as antagonists of the P2X7 nucleotide receptor: High selectivity for the human versus rat receptor homologues. Mol Pharmacol 1998; 54: 22–32.
Jiang LH, Mackenzie AB, North RA, Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol 2000; 58: 82–8.
Buell G, Chessell IP, Michel AD et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 1998; 92: 3521–8.
Modderman WE, Vrijheid-Lammers T, Lowik CW, Nijweide PJ. Removal of hematopoietic cells and macrophages from mouse bone marrow cultures: Isolation of fibroblast-like stromal cells. Exp Hematol 1994; 194–201.
Nijweide PJ, Modderman WE, Hagenaars CE. Extracellular adenosine triphosphate: A shock to hemopoietic cells. Clin Orthop 1995; 313: 92–102.
Di Virgilio F, Chiozzi P, Falzoni S et al. Cytolytic P2X purinoceptors. Cell Death Differ 1998; 5: 191–9.
Zanovello P, Bronte V, Rosato A et al. Responses of mouse lymphocytes to extracellular ATP. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol 1990; 145: 1545–50.
Zheng LM, Zychlinsky A, Liu C et al. Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 1991; 112: 279–88.
Humphreys BD, Rice J, Kertesy SB, Dubyak GR. Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. J Biol Chem 2000; 275: 26792–8.
Ferrari D, Los M, Bauer MK et al. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett 1999; 447: 71–5.
Sanz JM, Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1 beta release from microglial cells. J Immunol 2000; 164: 4893–8.
Wang Q, Wang L, Feng YH et al. P2X7-receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol 2004; 287: C1349–58.
Franke H, Gunther A, Grosche J et al. P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol 2004; 63: 686–99.
Suzuki T, Hide I, Ido K et al. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci 2004; 24: 1–7.
Sugiyama T, Kawamura H, Yamanishi S et al. Regulation of P2X7-induced pore formation and cell death in pericyte-containing retinal microvessels. Am J Physiol Cell Physiol 2004 [Epub ahead of print].
Courageot MP, Lepine S, Hours M et al. Involvement of sodium in early phosphatidylserine exposure and phospholipid scrambling induced by P2X7 purinoceptor activation in thymocytes. J Biol Chem 2004; 279: 21815–23.
Seman M, Adriouch S, Scheuplein F et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 2003; 19: 571–82.
Scheuplein F, Adriouch S, Glowacki G et al. Triggering of T-cell apoptosis by toxin-related ecto-ADP-ribosyltransferase ART2. Ann N Y Acad Sci 2003; 1010: 296–9.
Solini A, Chiozzi P, Morelli A et al. Enhanced P2X7 activity in human fibroblasts from diabetic patients: A possible pathogenetic mechanism for vascular damage in diabetes. Arterioscler Thromb Vasc Biol 2004; 24: 1240–5.
Elliott JI, Higgins CF. Major histocompatibility complex class I shedding and programmed cell death stimulated through the proinflammatory P2X7 receptor: A candidate susceptibility gene for NOD diabetes. Diabetes 2004; 53: 2012–7.
Chiozzi P, Sanz JM, Ferrari D et al. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. J Cell Biol 1997; 138: 697–706.
Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette–Guerin. J Exp Med 1994; 180: 1499–509.
Lammas DA, Stober C, Harvey CJ et al. ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z (P2X7) receptors. Immunity 1997; 7: 433–44.
Fairbairn IP, Stober CB, Kumararatne DS, Lammas DA. ATP-mediated killing of intracellular mycobacteria by macrophages is a P2X7-dependent process inducing bacterial death by phagosome–lysosome fusion. J Immunol 2001; 167: 3300–7.
Li CM, Campbell SJ, Kumararatne DS et al. Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. J Infect Dis 2002; 186: 1458–62.
Saunders BM, Fernando SL, Sluyter R et al. A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing of mycobacteria. J Immunol 2003; 171: 5442–6.
Falzoni S, Munerati M, Ferrari D et al. The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J Clin Invest 1995; 95: 1207–16.
Humphreys BD, Dubyak GR. Induction of the P2Z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. J Immunol 1996; 157: 5627–37.
Humphreys BD, Dubyak GR. Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998; 64: 265–73.
Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci USA 1991; 88: 8485–9.
Ferrari D, Villalba M, Chiozzi P et al. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 1996; 156: 1531–9.
Ferrari D, Chiozzi P, Falzoni S et al. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol 1997; 159: 1451–8.
Le Feuvre R, Brough D, Rothwell N. Extracellular ATP and P2X7 receptors in neurodegeneration. Eur J Pharmacol 2002; 447: 261–9.
Solle M, Labasi J, Perregaux DG et al. Altered cytokine production in mice lacking P2X7 receptors. J Biol Chem 2001; 276: 125–32.
Labasi JM, Petrushova N, Donovan C et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002; 168: 6436–45.
Baricordi OR, Ferrari D, Melchiorri L et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 1996; 87: 682–90.
Baricordi OR, Melchiorri L, Adinolfi E et al. Increased proliferation rate of lymphoid cells transfected with the P2X7 ATP receptor. J Biol Chem 1999; 274: 33206–8.
Budagian V, Bulanova E, Brovko L et al. Signaling through P2X7 receptor in human T cells involves p56 lck, MAP kinases, and transcription factors AP-1 and NF-kB. J Biol Chem 2003; 278: 1549–60.
Bradford M, Soltoff SP. P2X7 receptors activate protein kinase D and p427p44 mitogen-activated protein kinase (MAPK) downstream of protein kinase C. Biochem J 2002; 366: 745–55.
Gendron FP, Neary JT, Theiss PM et al. Mechanisms of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells. Am J Physiol Cell Physiol 2003; 284: C571–81.
Parvathenani LK, Tertyshnikova S, Greco CR et al. P2X7 mediates superoxide production in primary microglia and is upregulated in a transgenic mouse model of Alzheimer’s disease. J Biol Chem 2003; 278: 13309–17.
Graves LM, Guy HI, Kazlowski P et al. Regulation of carbamyl phosphate synthetase by MAP kinase. Nature 2000; 403: 328–32.
Whitmarsh AJ, Davis RJ. Trascription factor AP-1 regulation by mitogen activated protein kinase signal transduction pathways. J Mol Med 1996; 74: 589–607.
Wiley JS, Dubyak GR. Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 1989; 73: 1316–23.
Wiley JS, Chen R, Jamieson GP. The ATP4‒ receptor-operated channel (P2Z class) of human lymphocytes allows Ba++ and ethidium uptake: Inhibition of fluxes by suramin. Arch Biochem Biophys 1993; 305: 54–60.
Adinolfi E, Melchiorri L, Falzoni S et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002; 99: 706–8.
Wiley JS, Dao-Ung LP, Gu BJ et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: A molecular study. Lancet 2002; 359: 1114–9.
Thunberg U, Tobin G, Johnson A et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002; 360: 1935–9.
Guipaud O, Deriano L, Salin H et al. B-cell chronic lymphocytic leukemia: A polymorphic family unified by genomic features. Lancet oncol 2003; 4: 505–14.
Starczynski J, Pepper C, Pratt G et al. The P2X7 receptor gene polymorphism 1513 AC has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukemia. Brit J Haematol 2003; 123: 66–71.
Zhang LY, Ibbotson RE, Orchard JA et al. P2X7 polymorphism and chronic lymphocytic leukemia: Lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 2003; 17: 2097–100.
Nuckel H, Frey UH, Durig J et al. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: Absence of correlation with clinical outcome. Eur J Haematol 2004; 72: 259–63.
Sellick GS, Rudd M, Eve P et al. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004; 13: 1065–7.
Greig AV, Linge C, Healy V et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol 2003; 121: 315–27.
Slater M, Danieletto S, Gidley-Baird A et al. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology. 2004; 44: 206–15.
Jacobson KA, Javris MF, Williams M. Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 2002; 45: 4058–93.
Sanz JM, Chiozzi P, Di Virgilio F. Tenidap enhances P2Z/P2X7 receptor signalling in macrophages. Eur J Pharmacol 1998; 355: 235–44.
Ferrari D, Pizzirani C, Adinolfi E et al. The antibiotic polymyxin B modulates P2X7 receptor function. J Immunol 2004; 173: 4652–60.
Gargett CE, Wiley JS. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol 1997; 120: 1483–90.
Baraldi PG, Romagnoli R, Tabrizi MA et al. Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7 receptor. Bioorg Med Chem Lett 2000; 10: 681–4.
Baraldi PG, Makaeva R, Pavani MG et al. Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroiso-quinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moiety. Arzneim-Forsch Drug Res 2002; 52: 273–85.
Baraldi PG, del Carmen Nuñez M, Morelli A et al. Synthesis and biological activity of N-Arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J Med Chem 2003; 46: 1318–29.
Shemon AN, Sluyter R, Conigrave AD, Wiley JS. Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol 2004; 142: 1015–9.
Baxter A, Bent J, Bowers K et al. Hit-to-lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett 2003; 13: 4047–50.
Alcaraz L, Baxter A, Bent J et al. Novel P2X7 receptor antagonists. Bioorg Med Chem Lett 2003; 13: 4043–6.
Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565–73.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4